Ganga Pharmaceuticals Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Ganga Pharmaceuticals Ltd is ₹ 12 as of 12 Feb 15:30 . The P/E Ratio of Ganga Pharmaceuticals Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Ganga Pharmaceuticals Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Ganga Pharmaceuticals Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Ganga Pharmaceuticals Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Ganga Pharmaceuticals Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Ganga Pharmaceuticals Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Ganga Pharmaceuticals Ltd

Ganga Pharmaceuticals Ltd was incorporated as a Public Limited Company in Aug.'94 and promoted by Brij Mohan Sharma. he Company is engaged in the business of manufacturing & trading in Pharmaceuticals & allied products (Ayurveda). In Apr.'95, the company took over Ganga pharmaceuticals, a proprietory concern (owned by the same promoter), which was manufacturing and marketing ayurvedic products since the last two decades. The company which manufactures ayurvedic medicines, started commercial production in Apr.'95.
In Jul.'96, it came out with a public issue to part-finance the expansion programme involving setting up of a new manufacturing unit for the manufacture of ayurvedic medicines at Murbad, Maharashtra. The company which commenced exports in Jan.'96, has marketing arrangements with parties located in Saudi Arabia, Dubai, Italy, Romania and Russia to market its products in their respective regions.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Ganga Pharmaceuticals Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Ganga Pharmaceuticals Ltd or Sanofi India Ltd?

Market cap of Ganga Pharmaceuticals Ltd is 7 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Ganga Pharmaceuticals Ltd and Sanofi India Ltd?

The stock performance of Ganga Pharmaceuticals Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ganga Pharmaceuticals Ltd and Sanofi India Ltd?

As of May 6, 2026, the Ganga Pharmaceuticals Ltd stock price is INR ₹12.0. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Ganga Pharmaceuticals Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Ganga Pharmaceuticals Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.